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Abstract: 63 
Background: It has been suggested that there is some overlap between allergic rhinitis 64 
(AR), sinusitis and polyposis but it has not been fully documented.  65 
This study aimed to evaluate the prevalence of these coexisting diseases and their impact 66 
on bronchial asthma in the general population in Italy. 67 
Methods: In the frame of the multicentre Gene Environment Interactions in Respiratory 68 
Diseases (GEIRD) study, a postal screening questionnaire including questions about self 69 
reported symptoms of asthma, AR, AR with Sinusitis without Nasal Polyps (AR+SsNP)  70 
and ARwith Sinusitis with Nasal Polyps (AR+SwNP) was administered. Random samples 71 
of subjects aged 20-44 years (n=5162)  answered the postal questionnaire in 4 Italian 72 
centres (Pavia, Sassari, Torino, Verona). In allergic rhinitis subjects, the association 73 
among AR only, AR+SsNP, AR+SwNP, and bronchial asthma was estimated by the 74 
Relative Risk Ratio (RRR) using multinomial regression models.  75 
Results: The prevalence of AR in the sample was 25.4% (95%CI:24.2-26.6). The self-76 
reported diagnosis of AR+SsNP and AR+SwNPwas reported by 5.7% (95%CI:5.0-6.3) and 77 
by 1.2% (95%CI:0.9-1.5) of the subjects respectively. Current asthma was reported by 78 
17.5% of the AR subjects. In the adjusted multivariate analysis, the risk of having current 79 
asthma (RRR=2.31; 95%CI:1.29-4.15), of having at least 1 asthma attack/year 80 
(RRR=2.30; 95%CI:1.19-4.46)  and of having an emergency department admission for 81 
respiratory diseases (RRR=5.61; 95%CI:1.81-23.92) was higher for subjects with 82 
AR+SwNP , than subjects with AR only.  83 
Conclusions: The diagnosis of allergic rhinitis in the epidemiological setting includes 84 
heterogeneous upper airway diseases that affect the clinical features of AR and its 85 
interactions with asthma. 86 
 87 
88 
  
 
Introduction 89 
Allergic rhinitis (AR) is the most common immunologic disease and its prevalence is 90 
continuously on the increase, in particular in Western countries [1-3]. This not only affects 91 
the burden of the disease on patients [1-4], but it also has an impact on bronchial asthma  92 
and subsequently leads to an increased cost in health care use [1,6]. 93 
In epidemiology, validated questionnaires are used for the diagnosis of allergic rhinitis. An 94 
Italian study showed that the reliability of the question on allergic rhinitis seems adequate 95 
for epidemiological purposes and about 20% of the subjects who answered positively to 96 
the question on allergic rhinitis had had a negative  skin prick test or specific IgE levels [7].  97 
Studies focusing on the non-allergic upper airway diseases (such as chronic rhinitis and 98 
rhinosinusitis, with and without nasal polyps) showed the importance of the association 99 
between these diseases and severe/not controlled asthma suggesting that these upper 100 
airway diseases have a greater impact on asthma compared to allergy [8-12]. 101 
The overlap between allergic and non allergic upper airways diseases has been discussed 102 
in clinical studies, but its epidemiological results remain controversial and poorly defined 103 
[13-15]. 104 
This study aimed to evaluate the prevalence of AR, AR with Sinusitis without Nasal Polyps 105 
(AR+SsNP), AR with Sinusitis and with Nasal Polyps (AR+SwNP) and if the interaction 106 
between AR and bronchial asthma has been affected by concomitant upper airway 107 
diseases. 108 
  109 
  
 
Materials and Methods 110 
The study Gene Environment Interactions in Respiratory Diseases (GEIRD), is a  111 
multicentre survey on respiratory health in the general adult population, carried out 112 
between 2007 and 2010. In the frame of this study,  random samples of about 3000 113 
subjects from the general population aged 20 to 44 years old (male/female ratio=1) were 114 
selected from the registry of the local health authority in each of the four Italian centres: 115 
Pavia, Sassari, Torino, Verona [16].  116 
A screening questionnaire on respiratory symptoms was administered to eligible subjects 117 
by mail up to three times in case of non response and once by phone for subjects who had 118 
not responded by mail. 119 
The GEIRD screening questionnaire (available in www.geird.org), a modified version of 120 
questionnaires used in previous studies [17] included self reported information about 121 
respiratory symptoms (asthma, rhinitis and chronic bronchitis, cough and phlegm), 122 
environmental exposures (smoking habits) and education level as a proxy of socio-123 
economic status.  124 
 125 
Definitions and conditions 126 
The presence of AR was based on the answer to the questionnaire: “Do you have any 127 
nasal allergies including hay fever?”. Subjects who answered “yes” were classified as 128 
subjects with AR. If a subject answered “no” to the question he/she was classified as a 129 
subject without allergic rhinitis.  130 
Subjects with allergic rhinitis subjects were further classified as follows: 131 
  AR only: subjects with AR but without sinusitis (S) or Nasal Polyps (NP);  132 
  AR+SsNP: subjects with AR and who also answered “yes” to the question: “Do 133 
you suffer from sinusitis?”;  134 
  
 
  AR+SwNP: subjects with AR and Sinusitis and who also answered “yes” to the 135 
question: “Do you suffer from nasal polyps?”.  136 
The presence of asthma was defined as :  137 
  physician-diagnosed asthma if he/she answered “yes” to both of the following 138 
questions:” Have you ever had asthma?” and “ Was this confirmed by a doctor?”;  139 
  current asthma if he/she had physician-diagnosed asthma and took any 140 
medicines for asthma and had had an attack of asthma or at least one among 141 
the following asthma-like symptoms: wheezing, chest tightness, shortness of 142 
breath, in the last 12 months.  143 
As indicators of asthma severity/control we used: 144 
  the number of asthma attacks reported by the subject in the last 12 months 145 
classified as: “at least 1 asthma attack” and “>3 asthma attacks” ;  146 
  the presence of the asthma-chronic obstructive pulmonary disease (COPD) overlap 147 
syndrome, when a subject with current asthma answered “yes” to the following 148 
question: ‘‘Have you ever been told by a doctor that you have or had chronic 149 
bronchitis, COPD or emphysema?’’ 150 
  the intake of drugs for rhinitis and asthma based on the answers to the following 151 
questions: “Have you used any medicines for asthma in the last 12 months 152 
(including inhalers, aerosols or tablets)?” and “Have you used any medicines for 153 
rhinitis in the last 12 months (including inhalers, aerosols or tablets)?”.  154 
A four level variable was computed to evaluate which type of drugs a subjects used: 155 
“no medicines” if a subject answered “no” to both questions; “only asthma 156 
medicines” if a subjects took medicines for asthma and had not taken medicine for 157 
rhinitis in the last 12 months;  “only rhinitis medicines” if a subjects took 158 
medicines for rhinitis and had not taken medicine for asthma in the last 12 months; 159 
  
 
“both” if a subject had taken medicines for both rhinitis and for asthma in the last 12 160 
months. 161 
The presence of chronic cough and phlegm assessed by a positive answer to the question 162 
“Have you had coughing and phlegm on most days for a minimum of 3 months a year and 163 
for at least 2 successive years?”  164 
Also, a subject has been to Emergency Department (ED) for respiratory diseases if he/she 165 
answered “yes” to both of the following questions: “In the past 3 months have you been to 166 
Emergency Department for any reason, excluding accidents and injuries?” and “Was it due 167 
to respiratory problems?”. 168 
 169 
Confounders  170 
The potential confounders considered in the analysis were: gender, age (<30,30-39,≥40 171 
years), smoking habits (never smoker, ex smoker, current smoker), level of education 172 
(primary and lower secondary school, upper secondary school, degree), season of 173 
response (spring, summer, autumn, winter). In addition, type of contact (mail, phone), 174 
percentile rank of cumulative response centre-specific and centre were included as design 175 
confounders in the analysis.  176 
 177 
Statistical analysis 178 
Categorical variables were summarized with percentages, and were compared across 179 
strata by the Pearson’s Chi-squared test.  180 
The associations among different allergic rhinitis overlapping diseases (AR only, 181 
AR+SnNP, AR+SwNP), and other outcomes (diagnosed and current asthma, number of 182 
asthma attacks, asthma-COPD overlap syndrome, cough and phlegm and ED visits for 183 
respiratory diseases), were assessed by using multinomial regression models adjusted for 184 
potential confounders (gender, age, smoking habits, level of education, season of 185 
  
 
response, type of contact, percentile rank of cumulative response and centre). The 186 
Relative Risk Ratio (RRR) was estimated by choosing the group with AR only as the 187 
reference category. A p-value <0.05 was considered statistically significant. Statistical 188 
analyses were performed with STATA 12.1 (Stata Corp LP, College Station, TX, USA). 189 
  190 
  
 
Results 191 
Prevalence of allergic rhinitis and demographic data 192 
Overall 5162 subjects filled in the questionnaire in the 4 centres. The response rate was 193 
53%, ranging from 37.1% (Pavia) to 67.7% (Verona). The overall prevalence of allergic 194 
rhinitis in the study was 25.4% (95%CI 24.2-26.6). The subjects who self-reported 195 
diagnosis of AR+SsNP and AR+SwNP were 5.7% and 1.2% respectively.  196 
The subjects with AR were younger (table 2), fewer current smokers and they had a higher 197 
level of education than those without AR. The distribution of sex and education level 198 
among the three different groups of upper airway diseases (AR only, AR+SsNP and 199 
AR+SwNP) was statistically significant. The percentage of females was lower in subjects 200 
with AR+SwNP (36.1%) compared to the other two groups (51.8% and 63.5% for AR and 201 
AR+SsNP respectively). The level of education was significantly lower for subjects with 202 
AR+SwNP than for those of the other two groups (p=0.019). 203 
 204 
Overlapping upper airway diseases and asthma  205 
Overall, 23.8% of the subjects with AR had a physician diagnosed asthma and 17.5% of 206 
the subjects reported current asthma at the time of the survey (table 3). The prevalence of 207 
current asthma and the distribution of the control/severity markers of coexisting asthma 208 
varied significantly across the three different groups of AR subjects. In particular, the 209 
prevalence of current asthma increased from 15.8% in the group of AR only to 31.2% in 210 
the group AR+SwNP (p<0.001). The same statistically significant trend was found when 211 
considering the proportion of subjects who had at least one asthma attack in the last 12 212 
months (p=0.01), of subjects with the asthma-COPD overlap syndrome (p=0.03), of 213 
subjects with chronic cough and phlegm (p<0.001) and of those who had been 214 
hospitalized for respiratory diseases (p<0.01). 215 
  
 
The only exception to this general trend was the prevalence for subjects who had had 216 
more than three asthma attacks/year which, was similar in the three groups of upper 217 
airway diseases (p=0.76). 218 
In the multivariate analysis (table 4), after adjusting for potential confounders, the subjects 219 
with AR+SwNP, had a statistically significant increased risk of having current asthma 220 
(RRR=2.31; 95%CI:1.29-4.15), of having at least one asthma attacks in the last year 221 
(RRR=2.30; 95%CI: 1.19-4.46) and of having an ED admission for respiratory disease in 222 
the last 3 months (RRR= 5.61; 95%CI: 1.81-23.92) than subjects with AR only.  223 
Finally, the subjects with AR+SsNP and AR+SwNP had a statistically significant increased 224 
risk of having cough and phlegm (RRR=2.59; 95%CI: 1.89-3.54 and RRR=2.91; 95%CI: 225 
1.63-5.21 respectively) than subjects with AR only, while the asthma-chronic bronchitis 226 
overlap syndrome did not show statistically significant variations among the AR groups.  227 
 228 
Overlapping upper airway diseases and drug intake for rhinitis and asthma. 229 
Overall, 54% and 17.5% of subjects with AR had used medication for rhinitis and asthma 230 
respectively in the last year. After adjusting for potential confounders, in the multivariate 231 
analysis we found an increased risk that the subjects with AR+SsNP and AR+SwNP took 232 
medications both for rhinitis (RRR=1.91; 95%CI: 1.43-2.54 and RRR=2.46; 95%CI: 1.38-233 
4.40 respectively) and for asthma (RRR=1.52; 95%CI: 1.08-2.15 and RRR=2.27; 95%CI: 234 
1.23-4.19 respectively) than subjects with AR only.  235 
The overall distribution of the drugs intake for rhinitis and/or asthma across the three 236 
different groups of AR subjects is shown in the figure 1. The proportion of subjects who 237 
had not used medication in the last 12 months decreased from 46% in subjects with AR 238 
only to 28% in those with AR+S+P, whereas the use of medication for both rhinitis and 239 
asthma increased from 11% in the subjects with AR only to 28% in the subjects with 240 
AR+SwNP (p<0.001).  241 
  
 
When we considered the distribution of the drugs used only by the subjects with current 242 
asthma, stratified by no asthma attacks and at least one asthma attack, we found that the 243 
proportion who used drugs for asthma or for rhinitis was almost 65% in those who had not 244 
had an asthma attack and almost 95% in those who had had at least one asthma attack. 245 
The distribution of drugs used among the three groups of upper airway diseases was 246 
similar both for subjects with no asthma attack and at least one asthma attack (figure 2).  247 
 248 
 249 
250 
  
 
Discussion 251 
The most important finding of the study was that AR coexisted with sinusitis, with and 252 
without nasal polyps, in 6.9% of the general population. In addition, subjects with 253 
AR+SwNP had a higher likelihood of having more severe asthma than those with AR only.  254 
We also discuss the reliability of a self-reported diagnosis of sinusitis and the identification 255 
of subjects with nasal polyps as a subgroup  of those with AR.   256 
 257 
Prevalence of the upper airway diseases.  258 
Overall, about 25% of the subjects reported AR, about 6% reported AR plus sinusitis with 259 
and without nasal polyps  and these prevalence were similar across the centres.  260 
Concerns about the self-reported diagnosis of chronic rhinosinusitis [18,19] have led to the 261 
development of a specific questionnaire, to diagnose chronic rhinosinusitis in the 262 
epidemiological setting [20].  263 
A recent postal survey performed in Europe, using the EP3OS criteria questionnaire, found 264 
that the prevalence of chronic rhinosinusitis in the general population was 10.9%, with 265 
relevant variations of prevalence in the different geographical areas. In the only Italian 266 
center participating in this survey (Palermo) the prevalence was 10.8% (6,9% self-reported 267 
doctor-diagnosis) [21].  268 
In the EP3OS study, the diagnosis of chronic rhinosinusitis includes patients with and 269 
without nasal polyps, while the diagnosis of chronic rhino-sinusitis is limited only to the 270 
young adult subjects with AR in our survey. Although the diagnosis of sinusitis was only 271 
assessed in subjects with AR and consisted of a single question in the questionnaire, we 272 
might suppose that the prevalence of AR+SsNP found in our survey is coherent with that 273 
found in Italy. 274 
The prevalence of AR+SwNP found in our survey is in line with the estimated prevalence 275 
found both in Europe, which ranged from 2 to 4% of the general populations [22] and 276 
  
 
found in a specific survey in France (2.1%) [23]. However other studies [24] found a higher 277 
prevalence of polyposis than our survey but this could be due to the fact that the it was not 278 
in a population-based study. 279 
Overall, the reliability of the self-reported diagnosis of chronic rhinosinusitis and of 280 
AR+SwNP in our survey seems to be acceptable. 281 
 282 
Impact of allergic rhinitis on asthma 283 
The increase in drug intake for rhinitis  suggests an increase in severity from AR to 284 
AR+SwNP [25]. Moreover, the association between the severity of the upper airway 285 
diseases and their impact on asthma in the non adjusted analysis, seems to confirm the 286 
United Airways Diseases hypothesis [1,26]. After adjusting for potential confounders, the 287 
results show the presence of two different subsets of subjects within the AR group. The 288 
first one includes subjects with AR and with sinusitis, and the second one those with 289 
polyposis. 290 
In the first group, the increase in the proportion of subjects who took drugs for rhinitis and 291 
asthma suggests an increase in the severity of the upper airway diseases, which, does not 292 
correspond to an increase in the indicators of asthma severity (at least one asthma attack) 293 
and the ED visits for respiratory diseases.  294 
Despite the increase in the drug intake in the group of subjects with polyposis, it is evident 295 
that there is poor asthma control in this case.  296 
We hypothesize that the positive answer to the question on the presence of nasal polyps 297 
made it possible to identify two different asthma phenotypes in the AR subjects.  298 
In the first one, “early onset allergic asthma phenotype”, the disease could be determined 299 
by allergen-specific adaptative Th2 cells [27], and in the second one, “late onset 300 
eosinophilic asthma phenotype” could be driven by allergen independent innate lymphoid 301 
cells, and the responsiveness is characterized by refractory to steroids [28].  302 
  
 
Although these two pathogenic mechanisms are not mutually exclusive, as confirmed by 303 
the detection of allergic sensitization in patients with nasal polyposis, the role of the main 304 
pathogenic mechanism seems to be clear [29].  305 
When the severity of the upper airway diseases increased, a similar prevalence of the 306 
most unstable subset of asthmatic subjects (about 3% of them) was unexpected. This may 307 
be due to the poor adherence to the therapy [30].  308 
Furthermore, the prevalence of poor control, even in subjects with the mildest asthma, 309 
seems to be consistent with the recent studies on the presence of mast cells at the 310 
alveolar level in subjects with allergic rhinitis and uncontrolled asthma [31-33]. 311 
 312 
Strengths and Limitations 313 
The strength of this study is that we found the heterogeneity hidden in the diagnosis of 314 
allergic rhinitis obtained from the questionnaire. This is in contrast to the simple model 315 
used to compare allergic rhinitis and asthma (i.e. subjects with nasal polyp within those 316 
with AR), and our finding suggests that their interaction should be considered with more 317 
caution.  318 
The main limitation of our survey is that we could not determine the allergic pathogenesis 319 
of the upper airway diseases without cutaneous, serological [30] or any other clinical tests, 320 
which also  influence the reliability of the self-reported diagnosis of the upper airways 321 
comorbidity, such as the diagnosis of chronic rhinosinusitis with and without polyps. 322 
Another important limitation is the lack of any information about type, duration and the 323 
adherence to the therapy for rhinitis and asthma. The only information available was if a 324 
subject had used or not used drugs for rhinitis and/or asthma in the last 12 months.  325 
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TABLES AND FIGURES 506 
 507 
Table 1. Number of responders, response rate and prevalence of AR (with 95%CI) for 508 
each participating centre. 509 
centers n. of partecipating 
subjects 
(response rate (%)) 
prevalence (95%CI) 
AR 
overall 
AR only AR+SsNP AR+SwNP 
Verona 1746 (67,7) 24.4 (22.4-26.5) 17.8 (16.0-19.6) 5.5 (4.5-6.8) 1.1 (0.7-1.7) 
Pavia 966 (37,1) 25.0 (22.2-27.8) 18.7 (16.3-21.3) 5.2 (3.9-6.8) 1.0 (0.5-8.3) 
Turin 1205 (54,6) 27.0 (24.4-29.6) 21.0 (18.7-23.5) 5.0 (3.8-6.4) 0.9 (0.5-1.7) 
Sassari 1245 (53,0) 25.7 (23.2-28.2) 17.2 (15.2-19.4) 6.7 (5.4-8.3) 1.7 (1.1-2.6) 
overall 5162 (53,0) 25.4 (24.2-26.6) 18.6 (17.5-19.7) 5.7 (5.0-6.3) 1.2 (0.9-1.5) 
AR: Allergic Rhinits; SsNP:Sinusitis without Nasal Polyps; SwNP= Sinusitis with Nasal 510 
Polyps 511 
CI: Confidence Interval 512 
 513 
 514 
 515 
  516 
  
 
Table 2. characteristics of subjects stratified by presence of AR and different phenotypes 517 
for subjects with AR 518 
     subjects with AR  
variables without 
AR 
AR 
overall 
  AR 
only 
AR+Ss
NP 
AR+Sw
NP 
 
 n= 3795 n= 1294 p  n= 945 n= 288 n= 61 p 
gender (%)         
female  53.5 53.6 0.93  51.8 63.5 36.1 <0.001 
age (%)   0.041     0.516 
<30 26.2 29.7   30.4 29.5 19.7  
30-39 43.8 42.6   42.0 43.4 49.2  
≥40 30.0 27.7   27.6 27.1 31.1  
smoking habits (%)   0.048     0.181 
never smoker 54.7 57.6   59.1 54.7 47.5  
ex-smoker  18.0 18.6   17.2 22.1 23.0  
current smoker 27.3 23.8   23.7 23.2 29.5  
education (%)   0.006     0.019 
primary and lower 
secondary school 
23.4 19.2   18.4 18.8 32.8  
upper secondary 
school 
50.5 52.8   52.0 57.5 42.6  
degree 26.1 28.1   29.6 23.7 24.6  
season (%)   0.052     0.237 
spring 46.1 46.0   47.3 42.0 44.3  
summer 15.4 15.0   15.8 12.8 14.8  
autumn 32.4 30.7   28.7 37.2 31.1  
winter 6.1 8.3   8.2 8.0 9.8  
AR: Allergic Rhinits; SsNP:Sinusitis without Nasal Polyps; SwNP= Sinusitis with Nasal 519 
Polyps 520 
 521 
 522 
  523 
  
 
 524 
Table 3. crude prevalence (%) of different symptom or condition of asthma and drugs used 525 
in the last 12 months among subjects with allergic rhinitis, sinusitis and polyposis. 526 
 527 
Conditions  
AR 
overall 
AR 
only 
AR+SsNP  AR+SwNP p 
Physician-diagnosed asthma 23.8 23.0 24.8 31.7 0.28 
Current asthma 17.5 15.8 20.1 31.2 <0.01 
At least 1 asthma attack 11.5 10.2 13.9 21.3 0.01 
>3 asthma attacks 3.2 3.0 3.9 3.3 0.76 
Asthma-COPD overlap syndrome 3.0 2.6 3.2 8.6 0.03 
Drugs for asthma used in the last 12 months 17.5 15.2 22.4 29.3 0.001 
Cough and phlegm  22.7 17.9 34.9 40.7 <0.001 
ED admissions for respiratory diseases 1.1 0.8 1.4 5.1 <0.01 
Drugs for rhinitis used in the last 12 months 54.0 48.9 65.2 70.5 <0.001 
AR: Allergic Rhinits; SsNP:Sinusitis without Nasal Polyps; SwNP= Sinusitis with Nasal 528 
Polyps 529 
 530 
ED: Emergency Department 531 
 532 
  533 
  
 
Table 4. Association of different symptom or condition of asthma and among subjects with 534 
allergic rhinitis, sinusitis and polyposis. (Relative Risk Ratio (RRR*) and 95%CI) 535 
Conditions  AR only AR+SsNP AR+SwNP 
  RRR (95%CI) RRR (95%CI) 
Physician-diagnosed asthma 1 1.11 (0.81-1.52) 1.48 (0.83-2.64) 
Current asthma 1 1.35 (0.95-1.91) 2.31 (1.29-4.15) 
At least 1 asthma attack 1 1.39 (0.93-2.08) 2.30 (1.19-4.46) 
>3 asthma attacks 1 1.26 (0.61-2.61) 1.03 (0.23-4.54) 
Asthma-COPD overlap syndrome 1 1.08 (0.49-2.40) 2.71 (0.96-7.67) 
Drugs for asthma used in the last 12 months 1 1.52 (1.08-2.15) 2.27 (1.23-4.19) 
Cough and phlegm  1 2.59 (1.89-3.54) 2.91 (1.63-5.21) 
ED admissions for respiratory diseases 1 1.91 (0.54-6.71) 5.61 (1.81-23.92) 
Drugs for rhinitis used in the last 12 months 1 1.91 (1.43-2.54) 2.46 (1.38-4.40) 
*adjusted for gender, age, smoking habits, level of education, season of response, centre, 536 
type of contact and percentile rank of cumulative response. 537 
AR: Allergic Rhinits; SsNP:Sinusitis without Nasal Polyps; SwNP= Sinusitis with Nasal 538 
Polyps 539 
 540 
ED: Emergency Department 541 
RRR: Relative Risk Ratio 542 
CI: Confidence Interval 543 
 544 
545 
  
 
Figure 1. Distribution of subjects who used medication for rhinitis and asthma or both in 546 
the last12 months stratified by categories of rhinitis 547 
 548 
 549 
AR: Allergic Rhinits; SsNP:Sinusitis without Nasal Polyps; SwNP= Sinusitis with Nasal 550 
Polyps 551 
 552 
 553 
 554 
 555 
 556 
557 
  
 
Figure 2. Distribution of subjects with allergic rhinitis who used medication for rhinitis and 558 
asthma in the last 12 months stratified by categories of rhinitis and asthma attacks 559 
 560 
AR: Allergic Rhinits; SsNP:Sinusitis without Nasal Polyps; SwNP= Sinusitis with Nasal 561 
Polyps 562 
 563 
 564 
 565 
 566 
 567 
 568 
